Podium to Practice: ASH® 2025 – LYMPHOMA: Results from EPCORE DLBCL-3

Podium to Practice: ASH® 2025 – LYMPHOMA: Results from EPCORE DLBCL-3

Podium to Practice: ASH® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Carolyn Owen

Icon Chair Speaker

Speakers

Dr. Anca Prica

Dr. Kerry Savage

Studies / Trials Discussed

ID 63 – Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

This program has been made possible through unrestricted support from Eli Lilly and Merck.

Studies/trials discussed:

ID 63 – Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3
Tagged